Metabolic Diseases

About 415 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 642 million people by 20401. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, and basal insulin from our alliance partner Eli Lilly and Company, we are also focused on cardiometabolic indications with a high unmet medical need.

Type 2 Diabetes Mellitus (T2DM), the commonest form of diabetes, is a chronic, progressive disorder. The risk of developing T2DM, and of vascular diseases, arises from the common soil.2 Patients with T2DM, are also predisposed to serious complications of various organs and organ-systems, like heart-attack, heart-failure, paralysis, foot disease, kidney disease, eye disease, disease of nervous-system, and premature death.2-4

Indian patients are inherently prone to develop diabetes and its complications. Indian population is typically characterized as the ‘Thin-fat Indian phenotype’, with unique biological aspects, predisposing to increased cardio-metabolic risk. Lower muscle-mass, combined with higher visceral-fat content, results in lower metabolic tolerance in our population. Our patients tend to develop T2DM as well as cardiovascular diseases (CVD) a decade earlier, as compared to western counterparts.2-4

In our Indian patients, the risk of developing heart disease, and kidney disease, is particularly higher.2-7 In the Indian outpatient setting of diabetes:

  • Nearly 1 in every 3 patients with T2DM, has some manifestation of cardiovascular disease.5
  • Majority of male patients >45 years of age, and female patients >55 years of age, have increased risk of cardiovascular disease, even in absence of typical symptoms.6
  • Nearly 3 in every 5 patients have increase in risk for kidney disease, whereas about 1 in 5 patients have chronic kidney disease.5,7

As an organization, Boehringer Ingelheim stands for bringing value through innovation, with breakthrough solutions to improve the cardiovascular, kidney, and metabolic outcomes, improve the lives, and simplify the journey of patients with T2DM.

 

  •  

References

  1. ​IDF Diabetes Atlas, 9th edition, 2019.
  2. Stern P. Diabetes. 1995 Apr; 44:369-74.
  3. Yajnik CS. Eur J Clin Nutr. 2018;72(4):469-73.
  4. Pradeepa R, Nazir A, Mohan V. Heart Asia. 2012 Jan 1;4(1):69-76.
  5. I CaRe for Diabetes Steering Committee. JAPI. 2018 May;66 (suppl):s7-s15.
  6. Ghosal S, Sinha B et al. Indian Heart J. 2020 Mar-Apr;72(2):119-22.
  7. Kalra S. Presented at 48th Annual RSSDI conference (virtual), 2020 Nov, India.

 

We recognize that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.

Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.